University of Miami - Schiff Center for Liver Diseases
Welcome,         Profile    Billing    Logout  
 9 Trials 
44 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Levy, Cynthia
NCT04950127 / 2021-000007-21: Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Linerixibat, Placebo
GlaxoSmithKline
Pruritus
10/24
01/25
LLSAT, NCT04167358 / 2019-003158-10: Linerixibat Long-term Safety, and Tolerability Study

Recruiting
3
251
Europe, Canada, Japan, US, RoW
Linerixibat
GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited
Cholestasis
02/27
02/27
NCT05883748: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants with EPP

Enrolling by invitation
2/3
200
US, RoW
DISC-1459, Bitopertin, RO4917838
Disc Medicine, Inc
Erythropoietic Protoporphyria
06/28
06/28
SHIP, NCT03561584: Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis

Recruiting
2
42
US
Sulfasalazine, Azulfidine, Placebo
Brigham and Women's Hospital
Primary Sclerosing Cholangitis
09/24
11/24
NCT05308472: Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants with EPP

Completed
2
75
US
DISC-1459, Bitopertin, RO4917838, Placebo
Disc Medicine, Inc
Erythropoietic Protoporphyria
02/24
08/24
PACIFIC, NCT05525520 / 2021-002526-25: Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

Completed
2
62
Europe, Canada, US, RoW
EP547, Placebo
Escient Pharmaceuticals, Inc, Escient Pharmaceuticals, Inc.
Pruritus
07/24
09/24
NCT05239468 / 2022-001241-20: Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Active, not recruiting
2
60
US
Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo
Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc.
Primary Biliary Cholangitis
11/24
02/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT04884815 / 2020-005266-34: Study of UX701 Gene Transfer for the Treatment of Wilson Disease

Active, not recruiting
1/2
78
Europe, Canada, US
UX701, Placebo
Ultragenyx Pharmaceutical Inc, Ultragenyx Pharmaceutical Inc.
Wilson Disease
08/26
11/31
WIND-PSC, NCT06297993: Global Prospective, Observational Cohort of Adult Patients with Primary Sclerosing Cholangitis ( Study)

Recruiting
N/A
2000
Canada, US
PSC Partners Seeking a Cure
PSC
01/29
01/31
NCT01561157: Longitudinal Study of the Porphyrias

Recruiting
N/A
1500
US
Icahn School of Medicine at Mount Sinai
Acute Porphyrias, Cutaneous Porphyrias
06/25
06/25
Hassanein, Tarek
NCT01846663: Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

Terminated
4
6
US
Placebo, Rifaximin, XIFAXAN® Tablets
Bausch Health Americas, Inc.
Hepatic Encephalopathy
02/16
02/16
PRECIOSA, NCT03451292 / 2016-001789-28: Effects of Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites

Completed
3
410
Europe, Canada, US, RoW
Albutein 20% Injectable Solution, Standard medical treatment
Grifols Therapeutics LLC, Instituto Grifols, S.A.
Decompensated Cirrhosis and Ascites
05/24
05/24
APACHE, NCT03702920 / 2016-001787-10: Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%

Recruiting
3
380
Europe, US
SMT + PE-A 5%, Albutein 5%, Standard Medical Treatment, SMT
Grifols Therapeutics LLC, Instituto Grifols, S.A.
Acute-On-Chronic Liver Failure
10/26
10/26
ARGON-2, NCT04378010 / 2019-003876-38: A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

Terminated
2b
98
Europe, Canada, US, RoW
EDP-305 1.5 mg, EDP-305, EDP-305 2 mg, Placebo
Enanta Pharmaceuticals, Inc, Enanta Pharmaceuticals, Inc.
Non-Alcoholic Steatohepatitis
10/21
11/21
NAVIGATE, NCT04365868 / 2019-001983-31: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

Active, not recruiting
2b
357
Europe, Canada, US, RoW
belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo
Galectin Therapeutics Inc., Galectin Therapeutics Inc
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
12/24
12/24
PACIFIC, NCT05525520 / 2021-002526-25: Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

Completed
2
62
Europe, Canada, US, RoW
EP547, Placebo
Escient Pharmaceuticals, Inc, Escient Pharmaceuticals, Inc.
Pruritus
07/24
09/24
NCT05239468 / 2022-001241-20: Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Active, not recruiting
2
60
US
Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo
Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc.
Primary Biliary Cholangitis
11/24
02/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT06598943: A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
140
Europe, Japan, US, RoW
Eltrekibart, LY3041658, Mirikizumab, LY3074828, Placebo
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
12/27
09/28
NCT05104853: Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis

Active, not recruiting
1/2
42
US
CNP-104, Placebo
COUR Pharmaceutical Development Company, Inc.
Primary Biliary Cholangitis
01/26
01/26
NCT05490888: Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics

Recruiting
1
62
US
PHIN-214 Subcutaneous injection, Terlipressin derivative
PharmaIN
Cirrhosis, Liver, Liver Fibrosis, Ascites Hepatic
10/25
12/25
PhoenixAH, NCT06750588: Safety and Tolerability of NTR-101 in Patients with Acute Alcohol-Associated Hepatitis

Not yet recruiting
1
12
US
bacteriophage preparation, Bacteriophage preparation
Nterica Bio inc, Southern California Liver Centers
Alcohol-Associated Hepatitis
12/25
12/25
Forman, Lisa
NCT01846663: Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

Terminated
4
6
US
Placebo, Rifaximin, XIFAXAN® Tablets
Bausch Health Americas, Inc.
Hepatic Encephalopathy
02/16
02/16
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT05569759: A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)

Active, not recruiting
2
24
US
zetomipzomib, KZR-616, placebo, sterile water for injection, zetomipzomib in open-label extension
Kezar Life Sciences, Inc.
Autoimmune Hepatitis
02/25
08/25
NCT06699121: A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

Not yet recruiting
2
87
US
LB-P8 low-dose, LB-P8 high-dose, Placebo
LISCure Biosciences
Primary Sclerosing Cholangitis (PSC)
03/28
02/29
Nguyen, Laura
NCT02342444: Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)

Recruiting
4
606
US
Enoxaparin Sodium Injection 30 mg BID, Lovenox, Enoxaparin Sodium Injection 40 mg QD
Oregon Health and Science University
Trauma, Surgery, Deep Vein Thrombosis (DVT), Thromboembolic Events
12/24
03/25
CHIPS, NCT04834414: CHIlled Platelet Study ""

Recruiting
3
1000
US, RoW
Cold Stored Platelets, Room Temperature Platelets
Philip Spinella, University of Utah, University of Minnesota, Washington University School of Medicine, United States Department of Defense, University of Pittsburgh
Acute Blood Loss
03/25
04/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT05512026: Performance of the Poseidon System for Fluid Management During Water-aided Colonoscopy

Not yet recruiting
N/A
30
US
Feasibility Assessment
WAE Medical
Colonic Disease
01/23
03/23
EXB, NCT06775106: Exhaled Breath: A Novel Technique for Rapid Diagnosis of Respiratory Diseases and Infections

Recruiting
N/A
100
US
There is no intervention in this observational study
Oregon Health and Science University
Pulmonary Disease, Critical Illness
12/26
12/26
Dae, Katheryn
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Completed
3
407
Europe, Canada, US, RoW
Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir
Eiger BioPharmaceuticals
Hepatitis Delta Virus
10/22
03/23
NCT05239468 / 2022-001241-20: Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Active, not recruiting
2
60
US
Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo
Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc.
Primary Biliary Cholangitis
11/24
02/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
Yimam, Kidist
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT05569759: A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)

Active, not recruiting
2
24
US
zetomipzomib, KZR-616, placebo, sterile water for injection, zetomipzomib in open-label extension
Kezar Life Sciences, Inc.
Autoimmune Hepatitis
02/25
08/25
Thornton, Mary
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
ExTINGUSH, NCT04372615: The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis

Recruiting
2
116
Europe, US
Inebilizumab, UPLIZNA, Placebo
University of Utah
Autoimmune Encephalitis, Encephalitis
10/25
08/26
MoveS-it, NCT04602390: Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis

Completed
1
33
US
ANK-700, Placebo
Anokion SA
Multiple Sclerosis (MS), Relapsing Remitting Multiple Sclerosis
04/24
04/24
Herrera, Edisson Aguilera
SPARKLE, NCT04119843 / 2019-001599-12: Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function

Completed
3
87
Europe, US, RoW
Mangoral, Orviglance, CMC-001, ACE-MBCA
Ascelia Pharma AB
Known or Suspected Focal Liver Lesions, Severe Renal Impairment
02/23
02/23
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT01561157: Longitudinal Study of the Porphyrias

Recruiting
N/A
1500
US
Icahn School of Medicine at Mount Sinai
Acute Porphyrias, Cutaneous Porphyrias
06/25
06/25
Padila, Felisa Carmen
PACIFIC, NCT05525520 / 2021-002526-25: Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

Completed
2
62
Europe, Canada, US, RoW
EP547, Placebo
Escient Pharmaceuticals, Inc, Escient Pharmaceuticals, Inc.
Pruritus
07/24
09/24

Download Options